A 42-year-old woman presents with a 6-month history of episodic vertigo lasting 4–6 hours, accompanied by fluctuating sensorineural hearing loss, tinnitus, and aural fullness in the left ear. Audiometry confirms low-frequency sensorineural hearing loss. MRI of the internal acoustic meatus is normal. She has failed conservative management with salt restriction and diuretics for 3 months. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **definite Meniere disease** (episodic vertigo, fluctuating SNHL, tinnitus, aural fullness) that has failed first-line medical management (salt restriction + diuretics for 3 months). The next step is second-line pharmacological intervention before considering destructive surgical procedures. ## Management Hierarchy in Meniere Disease | Stage | Intervention | Indication | |-------|--------------|------------| | 1st line | Salt restriction, diuretics, vestibular rehabilitation | All acute/mild cases | | 2nd line | Intratympanic gentamicin OR corticosteroids | Failed medical therapy (3+ months) | | 3rd line | Endolymphatic sac decompression | Failed intratympanic therapy, hearing preservation desired | | 4th line | Vestibular nerve section or labyrinthectomy | Severe, refractory disease | ## Why Intratympanic Gentamicin? **Key Point:** Both intratympanic gentamicin and intratympanic corticosteroids are accepted second-line options after failed medical therapy. However, **intratympanic gentamicin is preferred when vertigo is the dominant and disabling symptom**, as in this case. **Mechanism of gentamicin:** 1. Selectively toxic to vestibular hair cells at low concentrations (preferential vestibulotoxicity over cochleotoxicity) 2. Produces chemical ablation of vestibular end-organ → gradual central compensation 3. Vertigo control rates: ~85–90% with careful titration protocols 4. Hearing preservation: ~70–80% of patients retain serviceable hearing **Why gentamicin over corticosteroids here:** - Intratympanic corticosteroids (dexamethasone/methylprednisolone) are most effective for **sudden SNHL** and **early/acute Meniere disease** with prominent hearing fluctuation - In **chronic, refractory Meniere disease** where vertigo is the primary disabling symptom, gentamicin's direct vestibular ablation provides superior and more durable vertigo control - This patient has already established fluctuating SNHL and 6 months of disabling vertigo — the priority is vertigo control, making gentamicin the preferred agent (Scott-Brown's Otorhinolaryngology; Sajjadi & Paparella, Lancet 2008) **High-Yield:** The distinction between the two intratympanic options hinges on the dominant symptom: corticosteroids for hearing preservation in early disease; gentamicin for vertigo ablation in refractory disease. ## Why Not the Other Options? **Intratympanic corticosteroids (Option A)** — Appropriate for sudden SNHL or early Meniere disease with prominent hearing fluctuation. Less effective for chronic, refractory vertigo control. Not the best choice when vertigo is the dominant refractory symptom. **Endolymphatic sac decompression (Option C)** — Third-line surgical option, reserved for patients who fail intratympanic therapy and wish to preserve hearing and vestibular function. Not indicated before intratympanic therapy has been attempted. **Translabyrinthine vestibular nerve section (Option D)** — Fourth-line destructive procedure with high hearing loss risk. Appropriate only after all conservative and chemical ablation options are exhausted. Premature at this stage. **Clinical Pearl:** Per Scott-Brown's Otorhinolaryngology and AAO-HNS guidelines, intratympanic gentamicin is the preferred second-line agent for **vertigo-dominant refractory Meniere disease**, while intratympanic corticosteroids are preferred when hearing preservation is the primary concern in earlier disease stages.